Article ID Journal Published Year Pages File Type
5825404 Clinical Therapeutics 2013 13 Pages PDF
Abstract
These results indicate that ticagrelor can weakly activate the metabolism of midazolam to its major 1′-hydroxy metabolite, and at the same time, seems to weakly inhibit midazolam 4′-hydroxylation. Furthermore, ticagrelor affects both hepatic and intestinal CYP3A activity.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, ,